TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14364 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Marie Fredslund Breinholt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Mutation, Tumor Suppressor Protein p53, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Large B‐cell lymphoma (LBCL) taxonomy has moved in the direction of a molecular classification, but further clinical experience is needed. We present high‐risk gene mutations, which predict outcome in an exploratory study of a consecutive real‐world cohort of patients with primary LBCL treated with R‐CHOP or R‐CHOP‐like therapy.
Methods
The study was a Registry Study Research Project. Sixty‐one patients with LBCL, who had a diagnostic tumor sample successfully examined with a 59‐gene next‐generation sequencing (NGS) panel as a part of routine clinical work, were included in an otherwise unselected cohort. Data were extracted from patient files and pathology reports.
Results
Mutations in NOTCH2 (HR 9.69; 95% CI [2.46–38.11]; p = 0.0012), PRDM1 (HR 3.54; 95% CI [1.03–12.22]; p = 0.045), and TP53 (HR 5.89; 95% CI [1.71–20.32]; p = 0.005) were significantly associated with inferior survival in patients with primary LBCL treated with intention to cure with at least three series of R‐CHOP or R‐CHOP‐like therapy. Neither MYD88 (HR 0.66; 95% CI (0.17–2.49), p = 0.54) nor CD79B (HR 0.84;95% CI (0.18–3.88), p = 0.82) mutations were associated with inferior survival.
Conclusion
With a targeted gene panel and NGS methodology feasible in daily diagnostic routine, we identified high‐risk gene mutations with a significant prognostic impact of which TP53 mutations were reproducible across validation cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- Danish Medicines Agency, Copenhagen, Denmark.
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
- Department of Pathology, Hvidovre Hospital, Hvidovre, Denmark.
ORCID-Profile: Marie Fredslund Breinholt, Lars Møller Pedersen
Zitieren
APA
Breinholt, M. F., Schejbel, L., Gang, A. O., Christensen, I. J., Nielsen, T. H., Pedersen, L. M., Høgdall, E., & Nørgaard, P. (2025). TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.14364
Vancouver
Breinholt MF, Schejbel L, Gang AO, Christensen IJ, Nielsen TH, Pedersen LM, et al. TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma. European Journal of Haematology. 2025. doi:10.1111/ejh.14364
BibTeX
@article{Breinholt2025,
author = {Breinholt, Marie Fredslund and Schejbel, Lone and Gang, Anne Ortved and Christensen, Ib Jarle and Nielsen, Torsten Holm and Pedersen, Lars Møller and Høgdall, Estrid and Nørgaard, Peter},
title = {TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14364}
}
EUVIMED